KYTHERA Biopharmaceuticals Presents Positive MRI Results from Phase IIb Study of ATX-101 in Reduction of Double Chin
April 13, 2013 at 21:18 PM EDT
KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF),